What is comprehensive genomic profiling?
Comprehensive genomic profiling (CGP) is a method of testing tumors that uses next-generation sequencing (NGS) to detect the four main classes of alterations known to drive cancer growth: base substitutions, insertions and deletions, copy number alterations (CNAs), and rearrangements or fusions. This testing can be performed on multiple specimen types including FFPE tissue, peripheral whole blood, bone marrow aspirate or extracted nucleic acid. CGP helps you better predict response or resistance to targeted- and immuno- therapies for more advanced cancer patients as compared to traditional molecular testing.
How is comprehensive genomic profiling different from single-gene or “hot spot” testing?
Single biomarker testing identifies alterations that are confined to a single gene, potentially missing clinically relevant mutations in additional genes. Gene hotspot testing may test multiple genes at a time but is confined to commonly altered regions within those genes, resulting in potentially missing other clinically relevant classes of alterations. Comprehensive genomic profiling detects the four main classes of genomic alterations across a broader panel of genes, oftentimes hundreds.
Which genes are tested?
Foundation Medicine tests look at more than 300 cancer-related genes:
FoundationOne CDx (324 DNA genes interrogated from a tissue sample)
FoundationOne Liquid CDx (324 DNA genes* interrogated from a simple blood draw)
FoundationOne Heme (406 DNA and 265 RNA genes interrogated from a variety of sample options)
*FoundationOne Liquid CDx is FDA-approved to report substitutions and indels in 311 genes, including rearrangements and copy number losses only in ALK and BRCA1/2 and copy number alterations in BRCA1/2 and ERBB2 (HER2). Comprehensive results across all 324 genes are reported as a laboratory professional service which is not reviewed or approved by the FDA.
Why is circulating tumor DNA (ctDNA) important?
ctDNA is released by tumor cells and collected by liquid biopsy. ctDNA allows biomarker testing and therapy selection when tissue biopsy is not available, or tissue is limited.1
Early information from ctDNA, through treatment response monitoring, could inform approaches to treatment by helping stratify patients with a high risk of resistance who might be candidates for escalation, versus those with a low risk of recurrence who might benefit from de-escalation to reduce risk of toxicities.2
Detectable ctDNA following surgery or neoadjuvant treatment for early-stage cancers, known as molecular residual disease, is associated with a high risk of recurrence and could provide valuable risk stratification information for making adjuvant treatment decisions.3
1 Rolfo et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. doi: 10.1016/j.jtho.2021.06.017.
2 Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17(12):757-770. doi:10.1038/s41571-020-0392-0
3 Tie J et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer [published correction appears in JAMA Oncol. 2019 Dec 1;5(12):1811]. JAMA Oncol. 2019;5(12):1710-1717. doi:10.1001/jamaoncol.2019.3616
How do I order a Foundation Medicine test?
Online Ordering: Order online by signing up for a Foundation Medicine account.
Email Ordering: To order by email, download and complete a test requisition form, along with attachments (pathology report, insurance information, and Advance Beneficiary Notice if required), and email to email@example.com.
You can also place an order via fax by sending a completed test requisition form along with attachments to 617-418-2290. Visit our Order a Test page to order specimen shipping kits for your practice.
How do I obtain the results of a Foundation Medicine test?
Foundation Medicine test reports can be accessed as soon as results are ready via our digital reporting portal or our mobile app – log in or sign up for a Foundation Medicine account or download our iOS app to obtain access. You can also receive access to results via secure email or request to have results faxed to you by reaching out to our Client Services team at firstname.lastname@example.org or by phone at +1 (888) 988-3639.
Is your lab CLIA Certified and CAP Accredited?
All Foundation Medicine comprehensive genomic profiling tests are run in CAP Accredited and CLIA Certified labs. View our certification documents here.
How do I sign-up for a Foundation Medicine account to order tests and access patient results online?
To sign-up for a Foundation Medicine account to place orders and access patient results online, complete the sign-up form here. To request access to our other online applications, such as FoundationInsights®, FoundationSmartTrialsTM, or our online biopharma resources, please contact your local Foundation Medicine representative or our Client Services department at email@example.com.
I’m having trouble logging in to my Foundation Medicine account – who do I contact to help?
For issues related to Foundation Medicine online accounts, please contact App Support at firstname.lastname@example.org.
I’m interested in signing my practice up for Foundation Medicine’s Epic or OncoEMR integration – who do I contact?
To learn more about our EMR integrations, please contact your Commercial Program Manager or reach out to our Client Services team at email@example.com or +1 (888) 988-3639.
Didn't find what you're looking for?
Our Client Services team is on hand to help. We are available Monday through Friday, 8 am to 8 pm Eastern Time.